Related Experiment Video
Updated: Feb 23, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
16.3K
Summary
A new liquid biopsy method detects cancer mutations in blood DNA, enabling early disease screening. This technique shows promise for identifying patients with early-stage cancers across multiple types.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Early cancer detection significantly improves patient outcomes and treatment efficacy.
- Current diagnostic methods can be invasive or lack sensitivity for detecting early-stage disease.
- Liquid biopsies offer a minimally invasive approach to identify cancer biomarkers.
Purpose of the Study:
- To develop and evaluate a novel liquid biopsy technique for early cancer detection.
- To assess the capability of the technique in identifying tumor-specific mutations from circulating DNA.
- To determine the sensitivity and specificity of the method in various cancer types.
Main Methods:
- Development of a sensitive assay to detect tumor DNA mutations in cell-free DNA (cfDNA) from blood samples.
- Application of the technique to analyze blood samples from patients with different types of cancer.
- Statistical analysis to evaluate the overall sensitivity and ability to detect early-stage disease.
Main Results:
- The liquid biopsy technique successfully detected tumor mutations in blood DNA.
- Overall sensitivity across four cancer types ranged from 56% to 83%.
- The method identified 62% of patients with early-stage cancer.
Conclusions:
- The developed liquid biopsy technique shows potential as a non-invasive screening tool for early cancer detection.
- This approach may aid in identifying individuals with early-stage malignancies, facilitating timely intervention.
- Further validation in larger cohorts is warranted to establish clinical utility.
